Despite this, Pfizer's head of vaccine research and development, Kathin Jansen, says the company was not helped financially by the program: "We have never taken any money from the USA government, or from anyone", Jansen told the New York Times.
Hancock said AstraZeneca, Oxford and the medicine regulator would have to study the results to see how best to administer the vaccine once it was found to be safe. Assuming it does get approval, the first people here in the United Kingdom can expect to get vaccinated by the end of December according to AstraZeneca the commercial parter that is producing the vaccine.
Slaoui said he and his family would be "happy" to receive the treatment. "Our plan is to be able to ship vaccines to the immunization sites within 24 hours of the approval", Moncef Slaoui, the chief scientist advisor for Trump's Operation Warp Speed, told CNN.
Another week and more good news in the fight against COVID-19. Sarah Gilbert, professor at Oxford's Nuffield Department of Medicine, said the better result with a smaller initial dose could be because this better "mimics what happens in a real infection".
The announcement comes after other trials of drugs developed by Pfizer/BioNTech and Moderna announced effectiveness above 90 percent. Oxford-AstraZeneca, however, added that the efficacy of vaccine could be around 90 per cent under one dosing regimen.
Patients must be 12 years or older, but the FDA said the prime candidates were 65-plus or had some chronic medical issues. Regeneron Pharmaceuticals Inc.'s antibody cocktail received an emergency use authorization from US drug regulators for treatment of early COVID-19 symptoms, adding to the expanding arsenal of therapies available to physicians.